




Building Sustainable Access at Scale



Viatriis in 2024

~1B Patients Reached Annually¹

>80B Doses of Medicine Sold

~1,400 Approved Molecules


>165 Countries & Territories Served

Access and Global Public Health

- > Supplied more than 240 medicines on the WHO Essential Medicines List, representing nearly 50% of the total list
- > Provided products that address the top 10 of the WHO's leading causes of death globally

Our People

- > Approximately 32,000 colleagues with industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise
- > 100% of colleagues globally with access to wellbeing and mental health resources




Financials

2024 Total Revenue:
\$14.7 Billion

2024 Net Sales:

- Brands
- Generics



Environment

- > Achieved an ~19% reduction of our scope 1 and 2 GHG emissions through the end of 2024 compared to our 2020 base year
- > Earned three British Standards Institute (BSI) Kitemark Certifications under the AMR Industry Alliance (AMRIA) Manufacturing Standard

Community

- > Donated more than 174 million doses of medicines for humanitarian and emergency relief efforts through our partners around the world
- > Continued our support of Rhiza Babuyile in South Africa to build three primary healthcare clinics



2024 Recognitions



Viartis is a global healthcare company focused on bringing high-quality medicines to patients through an exceptionally broad portfolio of generics, complex generics, brands and innovative products. With our portfolio, we seek to more holistically address healthcare needs globally. Our foundational strengths are the diversity of our portfolio, our global footprint and our mission to empower people worldwide to live healthier at every stage of life.

Our business and operating model is designed and implemented to deliver on our strategy to build and sustain access to medicine at scale. Underpinned by Viartis' relevance in meeting evolving healthcare needs, we seek to create value for and together with our key stakeholders. They include the people who trust our medicines every day, the health systems who rely on us, the people who make up Viartis, and our partners and the investors who believe in our ability to execute on our ambitious mission.

We are convinced that patients and health systems around the world are best served by a healthcare company applying a well-rounded and long-term approach, maintaining viability while working to manage inherent risks and opportunities, and continuously striving to advance sustainable operations and responsible practices in a focused way.

Viartis is a signatory to the United Nations Global Compact (UNGC) and is committed to the Compact's 10 principles related to human rights, labor, environment and anti-corruption.

WE SUPPORT



Viartis' Key Sustainability Areas

Viartis' Key Sustainability Topics: At the center of everything we do, Viartis works to create sustainable access to medicine to achieve better patient outcomes and advance global public health. We focus on key sustainability topics, all of which we pursue simultaneously to help drive our mission.

These key topics encompass four broad areas:

- **Reliable Supply and High-Quality Medicine:** manufacturing and distribution, including our supply chain and regulatory impact;
- **Our People:** managing talent, engaging employees and promoting workplace health and safety and inclusion;
- **Environmental Impact:** minimizing environmental impact – from climate change and energy to water and waste management; and
- **Governance and Ethical Practices:** managing inherent risks and encouraging opportunities and business ethics.



Partnering for More Sustainable Outcomes

No company can solve the pressing challenges of today alone. Collaboration and partnerships are key for meaningful and lasting impact. As part of advancing our work and encouraging more sustainable practices across our value chain, we are full and active members of the Pharmaceutical Supply Chain Initiative (PSCI), promoting responsible supply chain management and a founding member of the AMR Industry Alliance.



For more information, read the [Viartis 2024 Sustainability Report](#).

*The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2022 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viartis Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viartis medicines may be counted as multiple patients. Certain adjustments were applied in consideration of announced divestitures and to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.



[Viartis.com](#)



[LinkedIn](#)



[@ViartisInc](#)



[@ViartisInc](#)



[YouTube](#)



[Listen Well Podcast](#)

© 2025 Viartis Inc. All Rights Reserved. VIATRIS and the Viartis Logo are trademarks of Mylan Inc., a Viartis Company.